移植物闭塞,血管

摘要： 目的研究血管内皮生长因子(VEGF)及低氧诱导因子-1α(HIF-1α)与糖尿病合并动脉狭窄病人支架植入术后再狭窄关系。方法选取2016年9月至2018年2月华中科技大学同济医学院附属梨园医院糖尿病合并动脉狭窄病人188例,均行动脉支架植入治疗,支架植入前检测病人血清VEGFA及HIF-1α,糖、脂代谢指标及血清C反应蛋白(CRP),对病人追踪随访6个月,按是否发生冠脉再狭窄分为再狭窄组98例,未再狭窄组90例,比较两组病人VEGF及HIF-1α,糖、脂代谢指标及血清CRP水平差异,采用logistic分析糖尿病合并动脉狭窄病人支架植入术后再狭窄的风险因素。采用Pearson检验分析VEGF、HIF-1α与CRP的相关性。绘制受试者工作特征曲线(ROC曲线),分析VEGFA及HIF-1α对糖尿病合并动脉狭窄病人支架植入术后再狭窄的预测效能。结果再狭窄组及未再狭窄组病人血清糖化血红蛋白(HbA1c)≥7.2%、总胆固醇(TC)≥5.7 mmol/L、VEGF≥106.4 pg/mL、HIF-1α≥217.4 ng/mL、小而密低密度脂蛋白胆固醇(sLDLc)≥3.4 mmol/L、CRP≥11.6 mg/L、病变在分支动脉,支架植入长度≥3.4 cm、支架数目为2个及以上、支架直径<4.2 mm所占比例差异有统计学意义(63/98比34/90,64/98比31/90,61/98比31/90,63/98比27/90,62/98比40/90,62/98比17/90,71/98比41/90,62/98比34/90,26/98比10/90,71/98比31/90,均P<0.05)。多因素logistic回归分析结果显示,VEGF、HIF-1α、HbAH1c、CRP水平是动脉支架植入术后再狭窄的独立风险因素,支架直径是保护性因素(P<0.05)。相关分析结果显示,VEGF、HIF-1α与CRP水平呈现正相关关系(P<0.05)。VEGF、HIF-1α、CRP对糖尿病合并动脉狭窄病人支架植入术后再狭窄的评估效能:ROC-AUC(95%CI)分别为0.665(0.412~0.916)、0.761(0.552~0.971)、0.636(0.323~0.944)。结论糖尿病合并动脉狭窄病人血清VEGF、HIF-1α水平与支架植入术后再狭窄密切相关,检测血清VEGF、HIF-1α水平对冠脉再狭窄的发生具有较好的预测价值。

摘要： 目的 评估人工血管移植物内瘘(AVG)用于维持性血液透析的中期结果.方法 回顾性分析南方医科大学南方医院血管外科2014年1月至2016年12月收治的131例建立AVG患者的临床资料.结果 患者术后中位随访时间22.8个月(2～61个月).患者AVG术后平均初级通畅时间为(22.20±1.97)个月,1、2、3年初级通畅率分别为61.5％、36.6％和23.2％.AVG术后平均次级通畅时间为(38.30±2.30)个月,术后的1、2、3年次级通畅率分别为85.6％、68.6％和55.8％.AVG术后出现血栓形成65例(49.6％),通路狭窄50例(38.2％),移植物感染13例(9.9％),假性动脉瘤2例(1.5％),透析通路相关性肢端缺血综合征2例(1.5％),血清肿2例(1.5％).结论 AVG初级通畅率较自体动静脉内瘘(AVF)差,但通过修复手术能达到较满意的次级通畅率.术后规律随访,早期发现狭窄病变并进行相应处理,是维持AVG远期通畅的关键.

摘要： 目的 探讨超声引导下自体动静脉内瘘(arteriovenous fistula,AVF)腔内治疗入路选择与狭窄的特点之间的关系,以总结入路建立策略,辅助腔内治疗有效、快速、安全进行.方法 选择自2017年1月1日至2019年12月31日于北京市海淀医院因A V F狭窄而行超声引导腔内治疗患者,回顾性分析患者基本资料,内瘘狭窄的部位,入路建立部位、方向,入路相关并发症,腔内治疗手术情况,通过Spearman相关分析了解内瘘狭窄特点与入路建立的关系.结果 521例患者进行693例次球囊血管成形术治疗.在狭窄部位中以吻合口狭窄多见,约38.24％;其次流出静脉狭窄约占31.60％、流入动脉狭窄占23.38％(含足跟部位狭窄9.67％);2处及2处以上以上病变6.78％.累计建立入路768例次,以回流静脉入路最多见约88.31％,其次为肱动脉、回流静脉双入路7.50％,回流静脉双入路3.32％;肱动脉、桡动脉远端入路相对少见.行球囊血管成形术治疗技术成功率95.53％,临床成功率95.24％.入路相关并发症发生率为5.47％,以痉挛(3.52％)、血肿(1.82％)多见,其中回流静脉血肿及痉挛均见于在未穿刺区域建立入路者.当存在足跟部位狭窄选择肱动脉、回流静脉双入路时手术技术成功率为97.92％(47/48),入路相关并发症发生率2.08％(1/48)且肱动脉、回流静脉双入路建立与流入动脉足跟部位狭窄显著相关(相关系数0.606,P<0.001).结论 回流静脉是超声引导A V F狭窄腔内治疗的首选入路,对于复杂病变尤其合并流入动脉足跟狭窄者可考虑肱动脉与回流静脉双入路.

摘要： 随着社会的老龄化,下肢动脉硬化闭塞症成为常见的血管疾病.介入技术已成为治疗该病的主要手段,但支架内再狭窄对治疗效果的破坏仍困扰着临床医师.近10年来,针对支架内再狭窄的发生机制,涌现出各种新的预防及治疗技术,尤其相关器材的研制取得巨大进步,从药物涂层球囊、切割球囊到覆膜支架、可吸收支架等,均不同程度地降低了支架内再狭窄的发病率.本文对下肢动脉硬化支架内再狭窄的发生机制及治疗措施的相关临床研究的最新进展进行综述,着重对各种新器材临床应用效果进行总结评价.%Arteriosclerotic occlussive disease of the lower extremeties has become a common disease of aging society.Interventional technique is the main method of treating this disease,however,in-stent restenosis various and will degenerate itstherapeutic effect significantly and bring big trouble to clinicians.In the last decade,prevention and treatment techniques have emerged on the underlying mechanismofin-stent restenosis.Particularly,great improvement has been made,because of the development of related devices,such as drug coated balloons,cutting balloons,viabahn stentand bioresorbable stent,all of which could reduce the incidence of in-stent restenosisto varying degrees.In this paper,the latest progress of clinical research on the mechanism and treatment of in-stent restenosis is reviewed,particularly,the clinical effects of these newdevices are analyzed and summarized.

摘要： 目的 观察脑血管反应性(CVR)降低的大脑中动脉(MCA)重度狭窄患者血管内支架置入术后CVR的变化.方法 纳入症状性单侧MCA M1段重度狭窄伴CVR下降的患者10例,男性6例,女性4例,年龄61～73(66.6±3.6)岁.在吸入5％CO2及95％ O2的混合气体前后,用CT灌注(CTP)测定患者局部脑血流量,评价其CVR,患者均予以血管内支架成形术,术后6个月再次相同方法测定CVR,并与术前CVR比较.结果 10例患者均完成了血管内治疗与随访,置入支架前狭窄率70％～95％,置入支架后残余狭窄＜20％,6个月复查残余狭窄＜50％.置入支架前CVR值为-14％～ 29％,置入支架后CVR值-2％～24％,其中2例CVR仍未改善,8例患者CVR恢复正常.结论 血管内支架置入可以改善单侧MCA M1段严重狭窄患者的CVR.%Objective To observe the effect of stenting on cerebrovascular reactivity (CVR) in patients with severe symptomatic middle cerebral artery (MCA) stenosis.Motheds Ten patients (6 males 4 femals) with unilateral severe symptomatic MCA stenosis aged 61-73 years were included in this study.Their cerebral blood flow (CBF) was measured by CTP before and after 5％CO2and 95％O2 inhalation and their CVR was assayed.The CVR was assayed once more 6 months after the patients with decreased CVR underwent stenting.The CVR was compared before and after stenting.Results The 10 patients included in this study who underwent successful stenting were followed up.Their CVR was-14％--29％ before stenting and was-2％-24％ after stenting.Of the 10 patients,8 had no improvement in their CVR and 2 became normal in their CVR.Conclusion Stenting can improve the CVR in patients with unilateral severe MCA stenosis.

摘要： 目的:探讨冠状动脉旁路移植术(CABG)后移植血管包括大隐静脉桥(SVG)和左乳内动脉桥(LIMAG)的转归及相关的影响因素.方法:对自2010年至2015年92例行CABG后症状复发而复查冠状动脉(冠脉)自体血管造影和移植血管造影的结果和临床特征进行分析.92例患者中男性83例,女性9例,平均年龄(62.6±10.8)岁.52支LIMAG中,19支发生病变为LIMAG病变组,33支未发生病变为LIMAG无病变组;60支大隐静脉单独桥中,38支有病变的大隐静脉单独桥为大隐静脉单独桥病变组,22支无病变的大隐静脉单独桥为大隐静脉单独桥无病变组.统计分析SVG、LIMAG病变与传统动脉粥样硬化危险因素如年龄、性别、高血压、高脂血症、糖尿病、吸烟、冠心病家族史以及其他临床特点如心绞痛复发时间、冠脉造影距离CABG时间等、大隐静脉桥血管移植方式(序贯桥和单独桥)、自身靶血管搭桥前病变特点的相关性.结果:平均症状复发时间(35.10±24.7)个月.共有移植血管146支,其中LIMAG 52支,SVG 94支(单独桥60支,序贯桥34支),LIMAG通畅率显著高于SVG(63.5%vs 44.7%,P=0.030).SVG病变发生与CABG后症状复发时间呈正相关(OR=1.119,95%CI:1.002~1.249,P=0.046),与女性患者有相关倾向(P=0.065),与其他临床因素均不相关,而LIMA病变发生与各项临床因素均不相关.大隐静脉序贯桥通畅率明显高于单独桥(58.9%vs 36.7%,P=0.038).大隐静脉单独桥病变组(术前自体靶血管完全闭塞/狭窄=24支/14支)与无病变组(术前自体靶血管完全闭塞/狭窄者=17支/5支)的自体靶血管病变之间比较无差异(P=0.388);而LIMAG病变组中自体血管狭窄病变者明显多于LIMAG无病变组(LIMAG病变组:狭窄/闭塞=7支/12支;LIMAG无病变组:狭窄/闭塞=23支/10支),差异有统计学意义(P=0.04).结论:CABG后桥血管发生病变与冠心病传统的危险因素无明显相关性,术后SVG发生病变与CABG后心绞痛复发时间呈正相关.SVG序贯桥中远期通畅率高于单独桥.单独桥中CABG前自体靶血管血流状况将影响术后LIMAG的转归,而对SVG无明显影响.%Objective: To investigate the outcome and inlfuencing factors of graft vessels including saphenous vein graft (SVG) and left internal mammary artery graft (LIMAG) in patients after coronary artery bypass grafting (CABG). Methods: A total of 92 patients with post-CABG symptom recurrence from 2010 to 2015 were analyzed by angiography and clinical features for their native coronary vessel and graft vessel. There were 83 male and 9 female patients with the mean age of (62.6±10.8) years. The outcomes of graft vessel were assessed; correlation study was conducted between SVG, LIMAG lesions and traditional atherosclerosis risk factors like age, gender, hypertension, hyperlipidemia, diabetic mellitus, smoking, family history of coronary artery disease (CAD) with other clinical factors such as the time of angina recurrence, thetime from coronary angiography (CAG) to CABG, type of SVG (sequential graft or individual graft), the features of native target vessel lesions prior grafting. Results: The average time from CABG to symptom recurrence was (35.10±24.7) months. There were 146 grafts including 52 LIMAG and 94 SVG (60 individual and 34 sequential grafts), the patency rate of LIMAG was higher than SVG (63.5% vs 44.7%),P=0.030. SVG lesion was positively related to symptom recurrence (OR=1.119, 95% CI 1.002-1.249,P=0.046) and trended to female gender (P=0.065), while not related to other clinical factors; LIMGA lesion was not related to any clinical factors. The patency rate of sequential SVG was higher than individual SVG (58.9% vs. 36.7%,P=0.038). The native target vessel lesion (deifned by pre-operative occlusion/stenosis) was similar between individual SVG group (24/14) and no-lesion SVG group (17/5),P=0.388; while the native target vessel lesion in LIMAG group (7/12) was lower than no-lesion LIMAG group (23/10),P=0.04. Conclusion: Post-CABG lesion was not obviously related to traditional risk factors of CAD, post-SVG lesion was positively related to the time of post-CABG angina recurrence. SVG mid-and long-term patency in sequential graft vessel was higher than that in individual graft vessel. Pre-CABG native coronary blood lfow would affect the outcome of individual LIMAG but not SVG.

摘要： 近年来支架植入已被用于治疗复杂的股腘动脉段病变.由于该节段特殊的解剖学部位及生物学应力特点,支架植入后的再狭窄可导致患者缺血的复发,从而需要再次干预,是支架治疗策略的瓶颈.很多学者尝试应用普通球囊扩张、再次支架植入、切割球囊等策略治疗支架内再狭窄,然而结果并不理想.近期减容理念及药物涂层球囊被用于支架内再狭窄的治疗,获得了令人欣喜的结果.同时,使用覆膜支架或药物洗脱支架用于纠正原支架内断裂可得到相对满意的预后.本文总结近年来相关领域的治疗方法及证据,试图为临床治疗股腘动脉段支架内再狭窄提供思路.%Over the last few years,the treatment of complex femoropopliteal lesions led to the increasing use of stents in this challenging anatomical area.Whereas in-stent restenosis remains the Achilles' heel of stenting this segment,and leads to recurrent ischemia and repeated interventions.A majority of endovascular techniques have been evaluated to repair this complication,including plain balloon angioplasty,new stent deployment,cutting balloons but without satisfactory mid-and long-term results.More recently debulking and drug-eluting devices have been applied in femoropopliteal in-stent restenosis with promising results.And relining with a stent graft or drug-eluting stent of femoropopliteal in-stent restenosis can be considered in cases of stent fracture as this strategy has showed relatively optimal outcomes.The aim of this article is to analyze the evidence of those endovascular techniques for the treatment of femoropopliteal in-stent restenosis.

摘要： Objective To investigate the performance and safety of domestic peripherally absorbable magnesium alloy stent.Methods Sixteen absorbable magnesium alloy stents were implanted in the bilateral iliac-femoral arteries of 8 Chinese Agricultural University minipigs selected randomly with computer.The mean weight was (21.19± 1.93)kg.One pig was randomly selected by computer on 30th,45th,60th,75th,90th,105th,120th and 135th days after stent implantation and both stents were removed.The biochemical,imaging and histopathology index of the pig before and after stent placement were analyzed,t test was used to compare data collected before and after stenting.Results The biochemical index changes showed no statistical significance after stent implantation,the DSA indicated that vessel diameter was (4.39± 0.26) mm before stent implantation and (3.85±0.71)mm on the 30th to 135th day afterimplatation (t=3.041,P=0.008),the balance of vessel diameter before and after stenting ranged from 0 to 2.29 mm,with minimun on 30th day,and maximum on 90th day;HE and verhoeffvangieson showed significant stenosis of the arteries occurred on 60'h,90th and 120th day.From the 30th day to 135th day after stenting,the average diameter of residual lumen was (1.38±0.18) mm,the average area of residual lumen was (1.51±0.41) mm2,the average area of internal elastic lamina was (1.91t0.22) mm2,the average area of external elastic lamina was (4.79± 0.79) mm2,the average thickness of endothelium was (0.11 ±0.06) mm,the average area of new intima was (0.40±0.29) mm2,the average narrow area percentage was (21.96± 16.48)％.The stent absorbed gradually,and not completely absorbed until 135th day after stenting.Endometrial cells completely covered stent surface,and the stent did not break or collapse at all.Conclusions The peripherally absorbable magnesium alloy stents is safe and effective in animal experiment.Application of this stent in human should be investigated with further studies.%目的 初步探讨国产外周可吸收镁合金支架的安全性及有效性.方法 电脑随机选取8只中国农业大学Ⅱ系小型猪,平均体质量(21.19±1.93)kg,将16枚可吸收镁合金支架分别置人实验动物双侧髂股动脉中,分别于置入后第30、45、60、75、90、105、120、135天电脑随机抽取1只动物复查并取出2枚支架.分析支架置人前后血液相关生化指标、影像表现及组织HE、弹性纤维染色的病理形态.支架置人前后各项指标对比采用配对t检验.结果 支架置入前后白细胞及Mg、Na、K、CI离子,转氨酶、腺苷脱氨酶、肌酐、尿素氮、肌酸激酶各指标差异无统计学意义(P＞0.05).DSA造影显示,支架置人前髂股动脉直径(4.39±0.26) mm,置人后30～ 135 d血管直径(3.85±0.71) mm (t=3.041,P=0.008),置入前后血管直径差值0～2.29 mm,相差最小在第30天,最大在第90天;HE及弹性纤维染色提示支架置人后第60、90、120天血管出现明显狭窄.16枚支架,置入后30～135 d的平均残余管腔直径(1.38±0.18) mm、管腔面积(1.51±0.41) mm2、内弹力板围绕面积(1.91±0.22) mm2、外弹力板围绕面积(4.79±0.79)mm2、平均内膜厚度(0.11±0.06) mm、平均血管新生内膜面积(0.40±0.29) mm2、面积狭窄百分比(21.96±16.48)％.支架在体内逐渐降解,至第135天时仍未完全降解,未出现塌陷、打折,支架内膜覆盖完全.结论 该款外周可吸收镁合金支架在活体内应用安全、有效.

摘要： Objective To expose the effect and its potential mechanism of vinpocetine (Vinp) on the restenosis of dia⁃betic grafted veins. Methods Thirty-six Sprague-Dawley rats were randomized into saline control group and Vinp treat⁃ment group. The autologous jugular vein to carotid artery transplantation was performed in diabetic model rats. Normal sa⁃line or Vinp were intraperitoneally injected. The rats were sacrificed at 0, 2 or 4 weeks after surgery, then the grafted veins were harvested. The pathological sections were used to detect the effect of Vinp on intimal hyperplasia. The protein expres⁃sion of proliferating cell nuclear antigen (PCNA) was detected by immunohistochemical method, and which was described by cell proliferation index. The phosphorylation of NF-κB was detected by Western blot assay. Results The treatment of Vinp on intimal hyperplasia in vivo was significant at two weeks after surgery (17.06±5.10)μm versus control group (39.79±7.84μm, P<0.01), (30.94±5.18)μm versus (63.67±18.09)μm at four weeks after surgery (P<0.01). Vinp treatment effectively reduced the protein expression of PCNA [2 weeks:(21.07±1.38)%vs. (28.13±1.35)%,P<0.01;4 weeks:(31.73±1.38)%vs. (63.67 ± 18.09)%, P<0.01]. The treatment of Vinp inhibited phosphorylation of NF-κB at two weeks (1.08 ± 0.42 vs. 0.84 ± 0.12, P < 0.01). Conclusion Vinpocetine can effectively attenuate intimal hyperplasia in diabetic grafted veins, which might be related to its effect on inhibiting phosphorylation of NF-κB as well as inflammation.%目的：探讨长春西汀（Vinp）对糖尿病静脉桥移植术后再狭窄的影响及可能作用机制。方法36只SD大鼠随机分为对照组和Vinp组，通过建立糖尿病模型进行自体颈外静脉-颈总动脉移植，分别以生理盐水或者Vinp进行腹腔注射，于术后0周、2周及4周取移植静脉桥制作病理切片，测量内膜厚度，免疫组化法检测增殖细胞核抗原（PCNA）蛋白表达，通过细胞增殖指数定量描述。Western blot检测核转录因子（NF）-κB的磷酸化水平。结果 Vinp干预后明显减少糖尿病血管桥内膜增厚[术后2周：（17.06±5.10）μm vs.（39.79±7.84）μm，P<0.01；4周：（30.94±5.18）μm vs.（63.67±18.09）μm，P<0.01]，同时还降低糖尿病静脉桥PCNA蛋白的表达[术后2周：（21.07±1.38）%vs.（28.13±1.35）%，P<0.01；4周：（31.73±1.38）%vs.（63.67±18.09）%，P<0.01]，并抑制NF-κB的磷酸化（术后2周：1.08±0.42 vs.0.84±0.12，P<0.01）。结论 Vinp能有效抑制糖尿病静脉桥术后内膜增厚，其机制可能与抑制NF-κB通路，从而抑制炎症反应有关。

摘要： Objective To investigate the native vessel percutaneous coronary intervention (NV-PCI) and bridge vascu-lar interventional therapy (graft-PCI) strategies on prognosis in patients with coronary artery bypass grafting (CABG), by fol-lowing up the occurrence of major adverse cardiovascular events (MACE). Methods A total of 312 patients who relapsed chest pain after the CABG and had a successful interventional treatment were divided into two groups:215 patients for NV-PCI group and 97 patients for graft-PCI group. We observed cardiac death, acute myocardium infarction (AMI) and target vessel revascularization (TVR) after visiting the patients out of hospital for 34 months on average. The risk factors of MACE were analyzed by multivariable Logistic regression after the interventional treatment for the bridge vascular lesions. Re-sults The proportions of patients without MACE, AMI and TVR were significantly higher in NV-PCI group than those in graft-PCI group (P0.05).多因素Logistic回归分析显示,长桥龄[OR(95%CI):1.011(1.002~1.020),P=0.017]、糖尿病[OR(95%CI):2.375(1.414~3.989),P=0.001]及graft-PCI[OR(95%CI):1.873(1.090~3.219),P=0.023]是影响桥血管介入治疗预后的独立危险因素.结论 CABG术后桥血管病变原位血管介入治疗组临床预后明显优于桥血管介入治疗组;桥龄、糖尿病及graft-PCI是影响桥血管介入治疗临床预后的独立危险因素.

摘要： 本发明包括一种支架移植物（102），该支架移植物包括第一部分、第二部分和灌注窗（116），第一部分构造成与血管壁（100）配合，而第二部分构造成不与血管壁配合，灌注窗构造成允许血液流动。支架移植物还可包括位于第一部分和第二部分之间的过渡部分，而灌注窗可形成在第一部分、第二部分和/或过渡部分内。在各种实施例中，第一和第二部分之一可具有比另一个小的直径。同样地，在各种实施例中，过渡部分可以呈截头锥形状。

摘要： 本发明涉及通过施用嗜中性粒细胞弹性蛋白酶抑制剂例如阿维来司他进行器官排斥的治疗、特别是肺移植相关的闭塞性细支气管炎综合征的治疗。本发明还涉及移植物抗宿主病的治疗。

摘要： 本公开提供了血管移植物以及维持所述血管移植物的通畅的方法，所述血管移植物具有能够减少移植物周围纤维化荚膜形成的织构化微孔表面。

摘要： 本公开提供了血管移植物以及维持所述血管移植物的通畅的方法，所述血管移植物具有能够减少移植物周围纤维化荚膜形成的织构化微孔表面。

摘要： 本发明提供一种薄膜且具有充分的柔软性和低透水性的能够插入细的导管内的生物体管腔内移植物基材。本发明的生物体管腔内移植物基材，是将织物的至少一侧的面利用压延机机进行压制处理而制成，其中，上述织物含有总纤度维为1～80分特且单丝纤度小于0.1分特的纤维。

摘要： 一种血管移植物部署工具可包括：把手；细长心轴，其定位在把手的远侧；血管移植物，其至少部分围绕心轴同轴地设置；护套组件，其包括远侧护套部分和近侧护套部分，其中，远侧护套部分和近侧护套部分构造成将血管移植物以插入直径抵靠心轴约束；和致动器，其相对于把手可移动并接合护套组件，其中，致动器的操作使远侧护套部分和近侧护套部分中的至少一个纵向地分离以使血管移植物的至少一部分自由。此外，血管移植物能够从插入状态膨胀到部署状态，并且至少两个缝合封套位于血管移植物的相对端部之间。

摘要： 本发明涉及一种用于与工件血管移植物一起使用的容纳结构，其可包括：护套，其具有两个横向边缘；孔，其穿过护套限定在护套的横向边缘附近，其中，纵向相邻的孔彼此纵向地间隔开；和拉丝，其延伸穿过孔。一种医疗设备可包括：血管移植物，其能够从插入状态自膨胀到部署状态；和缝合封套，其位于血管移植物的一个端部处。一种部署工具可包括：心轴；血管移植物，其围绕心轴放置；和护套，其包裹在血管移植物周围，其中，护套将血管移植物压缩至插入直径。一种混合移植物可包括移植物和支架，其中移植物的端部附连到支架的端部。

摘要： 本发明包括一种支架移植物（102），该支架移植物包括第一部分、第二部分和灌注窗（116），第一部分构造成与血管壁（100）配合，而第二部分构造成不与血管壁配合，灌注窗构造成允许血液流动。支架移植物还可包括位于第一部分和第二部分之间的过渡部分，而灌注窗可形成在第一部分、第二部分和/或过渡部分内。在各种实施例中，第一和第二部分之一可具有比另一个小的直径。同样地，在各种实施例中，过渡部分可以呈截头锥形状。

摘要： 本发明公开了一种用于收集骨移植物材料的装置，该装置包括在其中延伸限定过滤器接纳空间的罐，该罐包括用于连接到真空源的连接件，罐的近侧端部包括第一锁定特征部和过滤器元件，该过滤器元件的尺寸和形状被设定成被接纳在罐的过滤器接纳空间内，过滤器元件包括延伸穿过过滤器元件的通道，该通道经由网状材料限定，并且过滤器元件的近侧端部包括与提取器结合的第二锁定特征部，该第二锁定特征部能够经由过滤器元件围绕过滤器元件的纵向轴线相对于罐的旋转而与罐的第一锁定特征部可释放地接合，提取器的尺寸和形状被设定成被接纳在过滤器元件的通道内，提取器限定其中的移植物材料接纳空间并且能够与提取器可释放地接合。

摘要： 在一个方面，本发明提供在患有与造血干细胞移植有关的移植物抗宿主病和/或弥漫性肺泡出血和/或静脉闭塞性病的人受试者中抑制MASP‑2‑依赖性补体活化的作用的方法。所述方法包括给予有需要的受试者有效抑制MASP‑2‑依赖性补体活化的量的MASP‑2抑制剂的步骤。